Case Report: Extensive Dermatitis Secondary to Severe Malnutrition, Zinc and Vitamin Deficiencies After Malabsorptive Bariatric Surgery.

Bariatric surgery is one of the most effective treatments currently available for obesity and its derived comorbidities. However, complications may occur, especially when malabsorptive surgeries like a biliopancreatic diversion is performed. We present the case of a female patient whose obesity was treated with this technique, and in the 9th year of follow-up developed an extensive dermatitis secondary to zinc deficiency and malnutrition, precipitated by therapeutic non-compliance. A close surveillance of early symptoms and signs of nutritional deficiencies as well as chronic supplementation of vitamins and trace elements is required; this case illustrates the relevance of periodical, lifelong visits to a medical physician with special training and experience in the management of post bariatric surgery patients in order to prevent, diagnosis and early treat related complications.

Circulating adiponectin expression is elevated and associated with the IL-15/IL-15Rα complex in obese physically active humans.

BACKGROUND: Adiponectin is an adipokine with oxidative, anti-inflammatory and antiatherogenic effects in several peripheral tissues; however, circulating adiponectin expression is reduced in cardio-metabolic diseases. The aim of this study was to ascertain whether regular physical activity mediates circulating adiponectin concentrations at baseline in an obese population. METHODS: Two hundred and twenty-one obese participants were divided into 6 groups according to gender, physical activity (PA), and type 2 diabetes mellitus (T2DM) diagnosis: A and B) obese PA females (N.=28) and males (N.=33); C and D) obese non-PA females (N.=40) and males (N.=40); E and F) obese non-PA females (N.=40) and males (N.=40) with T2DM. Serum adiponectin, IL-15 and IL-15Rα, blood glucose/lipid profile, and body composition were measured. RESULTS: Circulating adiponectin increased in PA participants compared to non-PA (ANOVA, P=0.001), finding higher concentrations in females compared to males (P<0.001), particularly in the PA group (P=0.005). Serum adiponectin was associated with age (R2=0.068), body mass (R2=-0.108), waist circumference (WC) (R2=-0.122), LDL (R2=-0.045), triglycerides (R2=-0.043), and serum IL-15Rα (R2=-0.243), as well as fat mass in females (R2=0.098), and WC in males (R2=0.112). CONCLUSIONS: Circulating adiponectin increased in obese PA participants (≥180 min/week) compared to non-PA counterparts, indicating that physical activity may mediate baseline adiponectin levels irrespective of the fat mass regulatory effect. The inverse relationship found between serum adiponectin and IL-15Rα may support the regulative role of the IL-15/IL-15Rα complex on this adipokine at baseline.

[Nutritional management of functional chronic diarrhea associated to malnutrition with peptide diet: a case report]. / Manejo nutricional de la diarrea crónica funcional asociada a desnutrición con una dieta peptídica: un caso clínico.

BACKGROUND: functional bowel disorders are characterized by an absence of structural or biochemical damage, but can lead to chronic diarrhea and intestinal malabsorption. If not properly treated, they predispose to a state of malnutrition that, depending on the underlying pathologies, could affect the evolution of other concomitant diseases. CASE REPORT: the relevance of this case stems from the fact that our 43-year-old patient, with multiple comorbidities, with progressive weight and muscle mass loss, after five years of inefficiency in the treatment of chronic diarrhea, achieves, on a peptide enteral formula basis, a good nutritional status and quality of life, which finally leads to the control of the chronic diarrhea and malnutrition. DISCUSSION: in the unintentional weight loss caused by long-term functional diarrhea, the choice of a peptide diet may have a fundamental role for a satisfactory patient's progress.

El síndrome de realimentación. Importancia del fósforo / The refeeding syndrome. Importance of phosphorus

El síndrome de realimentación es una enfermedad compleja que ocurre cuando se inicia el soporte nutricional después de un periodo de ayuno. La característica principal es la hipofosfatemia, sin embargo, también son comunes otras alteraciones bioquímicas como la hipomagnesemia, el déficit de tiamina y las alteraciones hídrico-electrolíticas. Su incidencia es desconocida, ya que no existe una definición universalmente aceptada, pero con frecuencia está infradiagnosticado. El síndrome de realimentación es un trastorno potencialmente fatal pero prevenible. Identificar a los pacientes en riesgo es crucial para mejorar su manejo. Si se diagnostica existen unas guías (NICE 2006) para orientar su tratamiento (pero basadas en un bajo grado de evidencia). Los objetivos de esta revisión son: destacar la importancia de este problema en pacientes desnutridos, discutir su fisiopatología y características clínicas y dar una serie de recomendaciones finales para disminuir el riesgo de desarrollarlo y facilitar su tratamiento

Refeeding syndrome (RS) is a complex disease that occurs when nutritional support is initiated after a period of starvation. The hallmark feature is the hypophosphataemia, however other biochemical abnormalities like hypokalaemia, hypomagnesaemia, thiamine deficiency and disorder of sodium and fluid balance are common. The incidence of RS is unknown as no universally accepted definition exists, but it is frequently underdiagnosed. RS is a potentially fatal, but preventable, disorder. The identification of patients at risk is crucial to improve their management. If RS is diagnosed, there is one guideline (NICE 2006) in place to help its treatment (but it is based on low quality of evidence). The aims of this review are: highlight the importance of this problem in malnourished patients, discuss the pathophysiology and clinical characteristics, with a final series of recommendations to reduce the risk of the syndrome and facilitate the treatment

Manejo nutricional de la diarrea crónica funcional asociada a desnutrición con una dieta peptídica: un caso clínico / Nutritional management of functional chronic diarrhea associated to malnutrition with peptide diet: a case report

Introducción: los trastornos funcionales del intestino se caracterizan por una ausencia de daño estructural o bioquímico, pero pueden causar diarrea crónica y malabsorción intestinal. Sin tratamiento adecuado, predisponen a un estado de desnutrición que, dependiendo de las patologías de base, podría condicionar la evolución de otras enfermedades concomitantes. Caso clínico: la relevancia de este caso se debe a que nuestra paciente pluripatológica, de 43 años de edad, con pérdida progresiva de peso y masa muscular, tras cinco años de ineficiencia en el tratamiento nutricional y soporte estándar de la diarrea crónica consigue, después de unos meses de tratamiento con dieta peptídica, un buen estado nutricional y calidad de vida, habiendo logrado controlar la diarrea crónica y la desnutrición. Discusión: en la pérdida inintencionada de peso que causa una diarrea de perfil funcional de larga evolución, la elección de una dieta peptídica puede ser muy útil para que la evolución del paciente sea satisfactoria

Background: functional bowel disorders are characterized by an absence of structural or biochemical damage, but can lead to chronic diarrhea and intestinal malabsorption. If not properly treated, they predispose to a state of malnutrition that, depending on the underlying pathologies, could affect the evolution of other concomitant diseases. Case report: the relevance of this case stems from the fact that our 43-year-old patient, with multiple comorbidities, with progressive weight and muscle mass loss, after five years of inefficiency in the treatment of chronic diarrhea, achieves, on a peptide enteral formula basis, a good nutritional status and quality of life, which finally leads to the control of the chronic diarrhea and malnutrition. Discussion: in the unintentional weight loss caused by long-term functional diarrhea, the choice of a peptide diet may have a fundamental role for a satisfactory patient's progress

The refeeding syndrome. Importance of phosphorus. / El síndrome de realimentación. Importancia del fósforo.

Refeeding syndrome (RS) is a complex disease that occurs when nutritional support is initiated after a period of starvation. The hallmark feature is the hypophosphataemia, however other biochemical abnormalities like hypokalaemia, hypomagnesaemia, thiamine deficiency and disorder of sodium and fluid balance are common. The incidence of RS is unknown as no universally accepted definition exists, but it is frequently underdiagnosed. RS is a potentially fatal, but preventable, disorder. The identification of patients at risk is crucial to improve their management. If RS is diagnosed, there is one guideline (NICE 2006) in place to help its treatment (but it is based on low quality of evidence). The aims of this review are: highlight the importance of this problem in malnourished patients, discuss the pathophysiology and clinical characteristics, with a final series of recommendations to reduce the risk of the syndrome and facilitate the treatment.

Efectiveness of long-term home parenteral nutrition with peripherally inserted central catheter: a case report / Eficacia de la nutrición parenteral domiciliaria de larga evolución con catéter de acceso periférico: a propósito de un caso

The use of home parenteral nutrition (HPN) in patients who can not obtain their nutritional requirements by the enteral route is increasing in recent years, allowing normalization lifestyle of patients. Neoplasm and mesenteric ischaemia are some of the diseases that most frequently require HPN in Spain. However, HPN is one of the cornerstones of the treatment of much less frequent illnesses as in the case of encapsulating peritoneal sclerosis. We present the case of a patient with encapsulating peritoneal sclerosis and HPN support for more than 7 years with a peripherally inserted central catheter (PICC) for over 6 years without complications and the autonomy to perform his normal business activity. Given the exceptional nature of the case we refer it to its publication.

El uso de la nutrición parenteral domiciliaria (NPD) en pacientes que no pueden alcanzar sus requerimientos nutricionales por la vía enteral está aumentando en los últimos años, permitiendo la normalización del estilo de vida de los pacientes. Entre las patologías que más frecuentemente precisan de la NPD en España destacan la neoplasia y la isquemia mesentérica. Sin embargo, la NPD constituye uno de los pilares básicos del tratamiento de enfermedades mucho menos frecuentes como es el caso de la esclerosis peritoneal encapsulante. A continuación presentamos el caso de un paciente diagnosticado de esclerosis peritoneal encapsulante con soporte NPD de más de 7 años de NPD con un catéter central de inserción periférica (PICC) para la NPD sin complicaciones y pudiendo realizar su actividad laboral habitual. Dado lo excepcional del caso lo remitimos para su publicación.

Eficacia de la nutrición parenteral domiciliaria de larga evolución con catéter de acceso periférico: a propósito de un caso / Effectiveness of long-term home parenteral nutrition with peripherally inserted central catheter: a case report

El uso de la nutrición parenteral domiciliaria (NPD) en pacientes que no pueden alcanzar sus requerimientos nutricionales por la vía enteral está aumentando en los últimos años, permitiendo la normalización del estilo de vida de los pacientes. Entre las patologías que más frecuentemente precisan de la NPD en España destacan la neoplasia y la isquemia mesentérica. Sin embargo, la NPD constituye uno de los pilares básicos del tratamiento de enfermedades mucho menos frecuentes como es el caso de la esclerosis peritoneal encapsulante. A continuación presentamos el caso de un paciente diagnosticado de esclerosis peritoneal encapsulante con soporte NPD de más de 7 años de NPD con un catéter central de inserción periférica (PICC) para la NPD sin complicaciones y pudiendo realizar su actividad laboral habitual. Dado lo excepcional del caso lo remitimos para su publicación (AU)

The use of home parenteral nutrition (HPN) in patients who can not obtain their nutritional requirements by the enteral route is increasing in recent years, allowing normalization lifestyle of patients. Neoplasm and mesenteric ischaemia are some of the diseases that most frequently require HPN in Spain. However, HPN is one of the cornerstones of the treatment of much less frequent illnesses as in the case of encapsulating peritoneal sclerosis. We present the case of a patient with encapsulating peritoneal sclerosis and HPN support for more than 7 years with a peripherally inserted central catheter (PICC) for over 6 years without complications and the autonomy to perform his normal business activity. Given the exceptional nature of the case we refer it to its publication (AU)

Efectos de exenatide LAR en diabetes mellitus tipo 2 y obesidad / Effects of exenatide lar in type 2 diabetes mellitus and obesity

Introducción: Los análogos GLP-1 han demostrado ser un tratamiento eficaz en el tratamiento de la diabetes mellitus tipo 2 (DM-2) y la obesidad. Objetivo: Evaluar la eficacia de exenatide LAR sobre la pérdida de peso, control glucémico, tensión arterial (TA) y perfil lipídico, en DM-2 y obesidad. Material y métodos: Estudio retrospectivo de pacientes en tratamiento con exenatide LAR durante 6 meses. Se recogieron datos demográficos (edad, sexo), antropométricos, glucemia basal, hemoglobina glicada (HbA1c), tensión arterial y perfil lipídico al inicio y a los 6 meses de tratamiento. Se ha realizado un análisis de regresión logística para evaluar posibles factores predictores de eficacia. Resultados: 30 pacientes (17 varones, edad media: 61,7±9,5 años) con DM-2 de 9,7±6,2 años de evolución. La HbA1c se redujo en 1,3% (IC95% 1,04-1,57, p <0,001), el peso en 2,8 kg (IC95% 1,67-3,96; p <0,001), y el IMC en 1,9 kg/m2 (IC95% 1,08-2,93; p <0,001). El colesterol total disminuyó 26,9 mg/dl (IC 95% 9,23-38,8, p = 0,003), el colesterol LDL 21,2 mg/dl (IC95% 7,56-34,9; p = 0,02), y los triglicéridos 53,9 mg/dl (IC 95% 46,4-77,1 mg/dl; p = 0,004). No se observaron diferencias estadísticamente significativas en los valores de TA y colesterol HDL. El 53,3% lograron un nivel de HbA1c <7%, el 66,6% perdieron peso, y el 43,3% de los pacientes ambos objetivos. Ninguna de las variables estudiadas se confirmó como predictora de respuesta al tratamiento. Respecto a los efectos secundarios, 53,3% pacientes refirieron molestias gastrointestinales (náuseas) y el 26,6% aparición de nódulos subcutáneos. Conclusiones: El tratamiento con exenatide LAR, en obesidad y DM-2, ha demostrado efecto beneficioso sobre el peso, el IMC, el control glucémico y lipídico, a pesar del largo tiempo de evolución de la diabetes en nuestros pacientes (AU)

Introduction: GLP-1 analogs have been shown to be an effective treatment of type 2 diabetes mellitus (DM-2) and obesity. Objectives: Evaluate the efficacy of exenatide LAR on weight loss, glycemic control, blood pressure (BP) and lipid profile, in DM-2 and obesity. Material and Methods: Retrospective study of patients treated with exenatide LAR for 6 months. Demographic data (age, gender), anthropometric, fasting glucose, glycated hemoglobin (HbA1c), blood pressure and lipid profile were collected at baseline and at 6 months after treatment. We performed a logistic regression analysis to assess possible predictors of efficacy. Results: 30 patients (17 male, mean age: 61.7 ± 9.5 years old) with DM-2 of 9.7 ± 6.2 years of evolution. HbA1c was reduced by 1.3% (95%CI 1.04-1.57; p <0.001), weight by 2.8 kg (95%CI 1.67-3.96, p <0.001) and BMI by 1.9 kg/m2 (95%CI 1,08-2,93; p <0,001). Total cholesterol decreased by 26.9 mg/dl (95%CI 9.23-38.8, p = 0.003), LDL cholesterol by 21.2 mg/dl (95% CI 7.56-34.9, p = 0.02) and triglycerides by 53.9 mg/dl (95%CI 46.4-77.1 mg/dl, p = 0.004). No statistically significant changes in blood pressure and HDL cholesterol were observed. 53.3% of patients got an HbA1c <7%, 66.6% lost weight, and 43.3% simultaneously achieved both of them. Neither of the studied variables was confirmed as a predictor of treatment response. Regarding side effects, 53.3% reported gastrointestinal discomfort (nausea) and 26.6% reported subcutaneous nodules of spontaneous resolution. Conclusions: Treatment with exenatide LA, in obesity and DM-2, has shown beneficial effect on lipid weight, BMI, glycemic control and lipid profile, despite the long duration of diabetes in our patients (AU)

[Effects of exenatide lar in type 2 diabetes mellitus and obesity]. / Efectos de exenatide lar en diabetes mellitus tipo 2 y obesidad.

INTRODUCTION: GLP-1 analogs have been shown to be an effective treatment of type 2 diabetes mellitus (DM-2) and obesity. OBJECTIVES: Evaluate the efficacy of exenatide LAR on weight loss, glycemic control, blood pressure (BP) and lipid profile, in DM-2 and obesity. MATERIAL AND METHODS: Retrospective study of patients treated with exenatide LAR for 6 months. Demographic data (age, gender), anthropometric, fasting glucose, glycated hemoglobin (HbA1c), blood pressure and lipid profile were collected at baseline and at 6 months after treatment. We performed a logistic regression analysis to assess possible predictors of efficacy. RESULTS: 30 patients (17 male, mean age: 61.7 ± 9.5 years old) with DM-2 of 9.7 ± 6.2 years of evolution. HbA1c was reduced by 1.3% (95%CI 1.04-1.57; p <0.001), weight by 2.8 kg (95%CI 1.67-3.96, p <0.001) and BMI by 1.9 kg/m2 (95%CI 1,08-2,93; p <0,001). Total cholesterol decreased by 26.9 mg/dl (95%CI 9.23-38.8, p = 0.003), LDL cholesterol by 21.2 mg/dl (95% CI 7.56-34.9, p = 0.02) and triglycerides by 53.9 mg/dl (95%CI 46.4-77.1 mg/dl, p = 0.004). No statistically significant changes in blood pressure and HDL cholesterol were observed. 53.3% of patients got an HbA1c <7%, 66.6% lost weight, and 43.3% simultaneously achieved both of them. Neither of the studied variables was confirmed as a predictor of treatment response. Regarding side effects, 53.3% reported gastrointestinal discomfort (nausea) and 26.6% reported subcutaneous nodules of spontaneous resolution. CONCLUSIONS: Treatment with exenatide LA, in obesity and DM-2, has shown beneficial effect on lipid weight, BMI, glycemic control and lipid profile, despite the long duration of diabetes in our patients.

Introducción: Los análogos GLP-1 han demostrado ser un tratamiento eficaz en el tratamiento de la diabetes mellitus tipo 2 (DM-2) y la obesidad. Objetivo: Evaluar la eficacia de exenatide LAR sobre la pérdida de peso, control glucémico, tensión arterial (TA) y perfil lipídico, en DM-2 y obesidad. Material y métodos: Estudio retrospectivo de pacientes en tratamiento con exenatide LAR durante 6 meses. Se recogieron datos demográficos (edad, sexo), antropométricos, glucemia basal, hemoglobina glicada (HbA1c), tensión arterial y perfil lipídico al inicio y a los 6 meses de tratamiento. Se ha realizado un análisis de regresión logística para evaluar posibles factores predictores de eficacia. Resultados: 30 pacientes (17 varones, edad media: 61,7±9,5 años) con DM-2 de 9,7±6,2 años de evolución. La HbA1c se redujo en 1,3% (IC95% 1,04-1,57, p.

Obstruction in patients with colorectal cancer increases morbidity and mortality in association with altered nutritional status.

Intestinal obstruction aggravates the prognosis of colorectal cancer (CRC) patients. The aim of this study was to carry out a comparative analysis of nutritional status and inflammatory response in CRC patients with or without intestinal obstruction. The study was carried out on 43 patients with CRC. Twenty-three of these patients had intestinal obstruction. Anthropometric measurements, serum protein content, acute phase reactants, and diagnostic and risk nutritional indices were analyzed. The presence of intestinal obstruction reduced albumin (31 +/- 5.2 vs. 36 +/- 4.2 g/l; P = 0.0025) and prealbumin (0.13 +/- 0.047 vs. 0.21 +/- 0.042 g/l; P = 0.0001) and increased C-reactive protein (49 +/- 43.8 vs. 14 +/- 16.7 mg/l; P = 0.006) and alpha1-antitrypsin (189 +/- 34.7 vs. 148 +/- 35.4 mg/dl; P = 0.0011). Intestinal obstruction was related to malnutrition (86% vs. 33%; P = 0.019) and Mullen's prognostic nutritional index (48 +/- 21.7 vs. 31 +/- 17.9; P = 0.038) in CRC patients. Mullen's nutritional risk index was inversely correlated to total cholesterol (r = -0.51; P = 0.0002) and albumin (r = -0.81; P = 0.0001). No correlation was found between Duke's tumor stages and acute phase response, inflammatory parameters, and malnutrition. In conclusion, intestinal obstruction occurred more frequently in CRC patients with malnutrition. The increased morbidity and mortality of CRC patients was also associated with acute phase response, inflammation, and low serum cholesterol and triglyceride concentration.